The Evaluatıon of The Effıcacy of Adalımumab in Refractory Non-Infectıous Uveıtıs Wıth Ultra-Wıdefıeld Fundus Fluoresceın Angıography

Abstract Aim: To investigate the efficacy of adalimumab in the cases with refractory non-infectious uveitis and evaluate retinal vascular leakage changes on ultra-widefield fundus fluorescein angiography.Methods: Twenty-three patients with refractory uveitis were included in study. Results: Forty-four eyes of 23 patients with non-infectious uveitiswere evaluated. Clinically active inflammation was present in 19 eyes (43.18%), while 25 (56.8%) were inactive. The mean drug burden was a 9.91±3.78 (5-21) in baseline, 7.3±4.25 at third and 8.0±4.71 at sixth month (p=0.022). The mean choroidal thickness was 256.65±43.63 μm in baseline, 240.49±36.73 μm at third and 224.81±34.91 μm at sixth month (p≤0.05). In terms of leakage extend, leakage was initially present in a mean of 2.95±4.55 clock hour quadrants, 2.41±3.91 at thirdand 1.76±3.44 at sixth month (p<0.001). Conclusion: Adalimumab was found to be effective in establishing inflammation control by reducing drug burden, controlling retinal vascular leakage and choroidal inflammation in refractory uveitis.